Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian D Davis

Showing results (61-70 of 281) with videos related to

Pageof 29
Sort By:
BJU International|May 16, 2019
Circulating oestrogen receptor mutations and splice variants in advanced prostate cancerLiang G Qu, Hady Wardan, Ian D Davis, et al.
Plos One|October 31, 2012
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanomaLisa M Ebert, Sarah E MacRaild, Damien Zanker, et al.
ANZ Journal of Surgery|April 23, 2021
Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic reviewMo Li, Jason Toniolo, Ruchira Nandurkar, et al.
Stem Cells (Dayton, Ohio)|November 22, 2011
Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profileMatthew Anaka, Claudia Freyer, Craig Gedye, et al.
The Lancet. Healthy Longevity|September 14, 2022
Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trialWee Kheng Soo, Madeleine T King, Alun Pope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2022
Reply to L. Marandino et alMartin R Stockler, Andrew J Martin, Haryana M Dhillon, et al.
BJU International|May 7, 2021
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocolAndrew Moe, Elizabeth Liow, Andrew Redfern, et al.
Twin Research and Human Genetics : the Official Journal of the International Society for Twin Studies|July 27, 2011
The Ets transcription factor ELF5 functions as a tumor suppressor in the kidneyErika J Lapinskas, Suzanne Svobodova, Ian D Davis, et al.
BJU International|October 17, 2013
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancerMun Sem Liew, Arun Azad, Ali Tafreshi, et al.
Future Oncology (London, England)|October 15, 2024
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studiesAndrew J Armstrong, Arun A Azad, Ciara Conduit, et al.
Pageof 29

Showing results (61-70 of 281) with videos related to

Sort By:
Pageof 29
BJU International|May 16, 2019
Circulating oestrogen receptor mutations and splice variants in advanced prostate cancerLiang G Qu, Hady Wardan, Ian D Davis, et al.
Plos One|October 31, 2012
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanomaLisa M Ebert, Sarah E MacRaild, Damien Zanker, et al.
ANZ Journal of Surgery|April 23, 2021
Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic reviewMo Li, Jason Toniolo, Ruchira Nandurkar, et al.
Stem Cells (Dayton, Ohio)|November 22, 2011
Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profileMatthew Anaka, Claudia Freyer, Craig Gedye, et al.
The Lancet. Healthy Longevity|September 14, 2022
Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trialWee Kheng Soo, Madeleine T King, Alun Pope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2022
Reply to L. Marandino et alMartin R Stockler, Andrew J Martin, Haryana M Dhillon, et al.
BJU International|May 7, 2021
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocolAndrew Moe, Elizabeth Liow, Andrew Redfern, et al.
Twin Research and Human Genetics : the Official Journal of the International Society for Twin Studies|July 27, 2011
The Ets transcription factor ELF5 functions as a tumor suppressor in the kidneyErika J Lapinskas, Suzanne Svobodova, Ian D Davis, et al.
BJU International|October 17, 2013
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancerMun Sem Liew, Arun Azad, Ali Tafreshi, et al.
Future Oncology (London, England)|October 15, 2024
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studiesAndrew J Armstrong, Arun A Azad, Ciara Conduit, et al.
Pageof 29